L-type voltage-gated calcium channel (Cav1.2) (LTCC)

L-type voltage-gated calcium channels (LTCCs), specifically the Cav1.2 isoform encoded by the CACNA1C gene, are the primary mediators of calcium influx in gastrointestinal (GI) smooth muscle cells [1][2]. These channels open in response to membrane depolarization, allowing calcium ions to enter the cytoplasm and bind to calmodulin, which subsequently activates myosin light chain kinase to initiate muscle contraction [1][3]. This process, known as excitation-contraction coupling, is fundamental to the regulation of gut motility and peristalsis [2]. Dysregulation of LTCC activity is implicated in various GI disorders, including irritable bowel syndrome (IBS) and achalasia, where abnormal contractile patterns occur [4]. Pharmacological agents such as pinaverium bromide and otilonium bromide target these channels to provide antispasmodic effects by blocking calcium entry [5]. While systemic calcium channel blockers like nifedipine are effective, they often carry risks of cardiovascular side effects, necessitating the use of GI-selective antagonists in treating motility issues [4][5]. The density and activity of these channels can be modulated by various hormones and neurotransmitters, making them a central hub for GI physiological control [1]. Therapeutic strategies often aim to balance the inhibition of these channels to alleviate pain without causing significant intestinal pseudo-obstruction or systemic hypotension [4].

Other names

Cav1.2CACNA1CVoltage-dependent L-type calcium channel subunit alpha-1CDihydropyridine-sensitive calcium channelCCHL1A1

Antagonism of the alpha-1C subunit (Cav1.2) to inhibit the influx of extracellular calcium ions into smooth muscle cells, thereby reducing muscle contractility and spasm [4][5].